Search research articles
Contact Us
Filters
Showing results (31-40 of 59) with videos related to
Page
of 6
Sort By:
Expert Review of Anticancer Therapy
|
January 28, 2015
Targeted therapy of acute myeloid leukemia
Benedito A Carneiro, Jessica K Altman, Jason B Kaplan, et al.
Hematological Oncology
|
September 22, 2009
Clofarabine in the treatment of poor risk acute myeloid leukaemia
Janusz Krawczyk, Naeem Ansar, Ronan Swords, et al.
AJR. American Journal of Roentgenology
|
December 24, 2009
Clinical utility of PET/CT in lymphoma
Carmel G Cronin, Ronan Swords, Mylene T Truong, et al.
Ejhaem
|
December 5, 2022
Molecular characteristics and outcomes in Hispanic and non-Hispanic patients with acute myeloid leukemia
Terrence Bradley, Deukwoo Kwon, Jorge Monge, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
October 1, 2016
An Evaluation of Treatment Patterns and Outcomes in Elderly Patients Newly Diagnosed With Acute Myeloid Leukemia: A Retrospective Analysis of Electronic Medical Records From US Community Oncology Practices
Esprit Ma, Vijayveer Bonthapally, Anita Chawla, et al.
Leukemia & Lymphoma
|
September 18, 2024
Thromboprophylaxis with intermediate dose enoxaparin during asparaginase containing induction for young adults with acute lymphoblastic leukemia
Hong De Sa, Thomas Deloughery, Andy Kaempf, et al.
Hematology Reports
|
December 21, 2011
Powered bone marrow biopsy procedures produce larger core specimens, with less pain, in less time than with standard manual devices
Larry J Miller, Thomas E Philbeck, Diana F Montez, et al.
American Journal of Hematology
|
December 15, 2015
Routine interim disease assessment in patients undergoing induction chemotherapy for acute myeloid leukemia: Can we do better?
Germán Campuzano-Zuluaga, Yehuda Deutsch, Matthew Salzberg, et al.
JCO Oncology Practice
|
May 9, 2025
Treatment Patterns and Real-World Outcomes of Molecular Subgroups in Patients With AML Receiving Frontline Venetoclax-Based Therapy
Curtis A Lachowiez, Anna Barcellos, Christina M Zettler, et al.
Leukemia Research
|
December 17, 2013
Nilotinib 300 mg BID as frontline treatment of CML: prospective analysis of the Xpert BCR-ABL monitor system and significance of 3-month molecular response
Michael E O'Dwyer, Ronan Swords, Arnon Nagler, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 59) with videos related to
Sort By:
Page
of 6
Expert Review of Anticancer Therapy
|
January 28, 2015
Targeted therapy of acute myeloid leukemia
Benedito A Carneiro, Jessica K Altman, Jason B Kaplan, et al.
Hematological Oncology
|
September 22, 2009
Clofarabine in the treatment of poor risk acute myeloid leukaemia
Janusz Krawczyk, Naeem Ansar, Ronan Swords, et al.
AJR. American Journal of Roentgenology
|
December 24, 2009
Clinical utility of PET/CT in lymphoma
Carmel G Cronin, Ronan Swords, Mylene T Truong, et al.
Ejhaem
|
December 5, 2022
Molecular characteristics and outcomes in Hispanic and non-Hispanic patients with acute myeloid leukemia
Terrence Bradley, Deukwoo Kwon, Jorge Monge, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
October 1, 2016
An Evaluation of Treatment Patterns and Outcomes in Elderly Patients Newly Diagnosed With Acute Myeloid Leukemia: A Retrospective Analysis of Electronic Medical Records From US Community Oncology Practices
Esprit Ma, Vijayveer Bonthapally, Anita Chawla, et al.
Leukemia & Lymphoma
|
September 18, 2024
Thromboprophylaxis with intermediate dose enoxaparin during asparaginase containing induction for young adults with acute lymphoblastic leukemia
Hong De Sa, Thomas Deloughery, Andy Kaempf, et al.
Hematology Reports
|
December 21, 2011
Powered bone marrow biopsy procedures produce larger core specimens, with less pain, in less time than with standard manual devices
Larry J Miller, Thomas E Philbeck, Diana F Montez, et al.
American Journal of Hematology
|
December 15, 2015
Routine interim disease assessment in patients undergoing induction chemotherapy for acute myeloid leukemia: Can we do better?
Germán Campuzano-Zuluaga, Yehuda Deutsch, Matthew Salzberg, et al.
JCO Oncology Practice
|
May 9, 2025
Treatment Patterns and Real-World Outcomes of Molecular Subgroups in Patients With AML Receiving Frontline Venetoclax-Based Therapy
Curtis A Lachowiez, Anna Barcellos, Christina M Zettler, et al.
Leukemia Research
|
December 17, 2013
Nilotinib 300 mg BID as frontline treatment of CML: prospective analysis of the Xpert BCR-ABL monitor system and significance of 3-month molecular response
Michael E O'Dwyer, Ronan Swords, Arnon Nagler, et al.
Page
of 6